RMM RFP Guidance for Applicants

	Discovery Science	Translational Research	Clinical Trial	Infrastructure
Funding Amount*	Max of $200K	Max of $400K	Max of $500K - larger budgets may be allowable with adequate justification	Max of $100K - larger budgets may be allowable with adequate justification
Funding Period	Up to 2 years	Up to 2 years	Up to 4 years	1 year
Objective	Support rigorous studies addressing critical basic knowledge gaps in the biology of stem cells and regenerative medicine approaches and to advance stem cell-based tools	Promote the identification and translational development of regenerative medicine-based therapeutics, diagnostics, medical devices, or tools	Support the completion of a clinical trial for a regenerative medicine-based intervention that addresses an unmet medical need	Funding for infrastructure to enhance the organization's ability to develop commercializable regenerative medicine-based therapeutics, diagnostics, medical devices, or tools
Eligibility	Minnesota-based academic institutions and small-businesses performing scientific and/or medical research in the state of Minnesota are eligible for this opportunity. Small businesses (the "Entity") must be based, owned (≥50%), and operating in the state of Minnesota. For this definition, a small business must have at least 2 and no more than 100 affiliated full- or part-time employees. Entities must be registered with the state of Minnesota's Secretary of State Office (http://www.sos.state.mn.us/business-liens) prior to the application being submitted. The project Principal Investigator (PI) must be an employee of the applicant organization and authorized by the applicant organization to conduct the research and assume the responsibilities of the PI.			
Funded Activities	● Basic research into stem cell mechanisms or genetics ● Investigating stem cells as tools for drug discovery, development and disease modelling ● Research tools related to diversity, equity and inclusion ● Modeling of cells/tissues (omics) ● Auxiliary research (biomarker discovery, gene editing, imaging tools)	● Activities that will lead to selection and/or translation of a novel candidate therapeutic, diagnostic, medical device, or tool for use in developing new drugs, devices, or disease models ● Proof of concept studies ● Developing a Target Product Profile ● IND and IDE-enabling studies	● All activities necessary for the planning, conduct, and completion of a clinical trial ● Correlative studies or comparability studies associated with a clinical trial ● Activities intended to promote and uphold principles of diversity, equity, and inclusion in the conduct of the study	● Development of infrastructure to manufacture, test, gain regulatory approval, and market regenerative products ● Purchase of non-expendable equipment or instrumentation to improve infrastructure for the development of regenerative medicine products ● Implementing Quality Management System & GMP standards
Review Criteria**	● Does the project hold the necessary significance and potential for impact? ● Is the rationale sound? ● Is the project well planned and designed? ● Is the project feasible?			

*Includes both direct and indirect costs
**Specific review criteria will be tailored to each RFP based on project type and expected outcomes.